Talk:Galderma

L'Oréal will pay €3.4 billion (USD$4.63 billion) for the remaining 27.3 million shares.[6]

This doesn't seem to make a whole lot of sense here, since Nestle bought Galderma. The source is not available anymore, unfortunately. Maybe the sentence is about a separate transaction? In this case, it should be deleted from the Galderma-page. - 130.60.152.125 (talk) 13:50, 3 March 2015 (UTC)

Proposal for updates
Hello,

We would like to add two pieces of content (either at the end of the History section, or into the Activities section), following the results of clinical studies, and are seeking the approval of the community.

First piece of content:

In June 2022, Galderma announced positive results in two Phase III trials for liquid botulinum toxin A, showing RelabotulinumtoxinA significantly reduced frown line severity and was well tolerated. This result primes the company to apply for approval in the US and other global markets.

Source: https://aestheticmed.co.uk/site/shownewsdetails/galderma-announces-positive-results-in-two-phase-i

Second piece of content:

In June 2022, Galderma announced positive data from Phase III trial, showing efficacy and safety of nemolizumab in patients with prurigo nodularis. Nemolizumab is a monoclonal antibody that blocks the signaling of IL-31, a neuroimmune cytokine involved in the pathogenesis of prurigo nodularis.

Source: https://clinicaltrials.gov/ct2/show/NCT04501666, https://finance.yahoo.com/news/galderma-announces-positive-data-phase-060000232.html

Many thanks for your feedback and advice,

Galderma21 Galderma21 (talk) 13:00, 20 December 2022 (UTC)

extensive COI editing
Article has been extensively edited by User:Galderma21, it needs a thorough review. In addition, User:Galderma21 appears to be a shared account by their own admission. — Preceding unsigned comment added by 46.140.57.254 (talk) 20:05, 25 April 2024 (UTC)